The phrase "a decrease in potency" is correct and usable in written English.
It can be used in contexts discussing the reduction of effectiveness or strength, often in scientific, medical, or technical discussions.
Example: "The study revealed a significant decrease in potency of the drug after prolonged storage."
Alternatives: "a reduction in effectiveness" or "a decline in strength."
A decrease in potency was however observed for compounds 35, 36, and 37 bearing a more linear side chain as para-substituent.
The results suggest that the substitution of a hydrogen with a long side-chain or bulky group generally induces a decrease in potency at M1 and M3 subtypes, while a general increase in this parameter is obtained at M2 subtype.
Additionally, removal, extension, or substitution of the benzylic methylene group resulted in a decrease in potency.
Mutation of H26 to alanine caused a decrease in potency, which was more pronounced for OX1 than for OX2.
Mutation of A23 to glycine caused a decrease in potency, which was more pronounced for OX1 than for OX2.
More effects were seen with AM2; G35A, T37A, I41A and Q45A all showed a decrease in potency.
The increase in LOOH level from 0 to 5 µM was accompanied by a decrease in zileuton potency for inhibition of oxoETE synthesis (see Figure 12, dashed line) in comparison with its potency to inhibit LTA4 synthesis (IC50LTA4
Mutation of the conserved R10 to alanine resulted in a decrease in the potency of OxB with respect to both OX1 and OX2 receptors.
Mutation of the nonconserved S18 to alanine resulted in a decrease in the potency to OX2 but had no effect on OX1.
L34A, T37A, I41A, M42A, Q45A and I52A all showed a decrease in AM potency, although the effect of T37A was not statistically significant (Table 2001; Figure 1).
We believe this to be the first demonstration of an increase in antibody affinity leading to a decrease in biological potency, in contrast to the many published examples of positive correlations between the two attributes.
